NAFTIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NAFTIN (NAFTIN).
Naftin (naftifine hydrochloride) is an allylamine antifungal agent that inhibits squalene epoxidase, blocking the conversion of squalene to lanosterol, thereby disrupting ergosterol synthesis in fungal cell membranes.
| Metabolism | Following topical application, systemic absorption is minimal (<6%). The absorbed fraction undergoes hepatic metabolism via cytochrome P450 enzymes, primarily oxidation and glucuronidation. |
| Excretion | Primarily hepatic via CYP450 metabolism; renal excretion of metabolites accounts for approximately 70-80% of elimination, with <1% excreted unchanged in urine. Fecal excretion accounts for 10-20%. |
| Half-life | Terminal elimination half-life is approximately 2-4 hours, but clinical effects persist longer due to lipophilic properties and tissue binding. Dosing intervals of 12-24 hours are recommended. |
| Protein binding | Approximately 80-85% bound to serum albumin. |
| Volume of Distribution | Apparent volume of distribution is approximately 1.4 L/kg, indicating extensive distribution into tissues including the stratum corneum, dermis, and sebaceous glands. |
| Bioavailability | Topical: Systemic bioavailability is <3% due to minimal percutaneous absorption; does not require dose adjustment for hepatic or renal impairment. |
| Onset of Action | Topical application: Onset of antifungal action occurs within 24-48 hours, with symptomatic improvement seen by 1 week. |
| Duration of Action | Duration of action after last dose: Clinical mycologic cure continues for up to 1-2 weeks after cessation of therapy. Relapse may occur if treatment is discontinued prematurely. |
Apply a thin layer to affected area and surrounding skin once daily (naftifine 1% cream) or twice daily (naftifine 1% gel) for 2-4 weeks, depending on infection type.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. Naftifine is primarily topical with negligible systemic absorption. |
| Liver impairment | No dose adjustment required for hepatic impairment due to minimal systemic absorption. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; use only if clearly needed. |
| Geriatric use | No specific dose adjustment; apply same as adult dosing. Elderly may use thinning skin precautions. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NAFTIN (NAFTIN).
| Breastfeeding | It is not known if naftifine is excreted in human milk following topical application. Minimal systemic absorption suggests low risk, but caution is advised. M/P ratio is not established. |
| Teratogenic Risk | NAFTIN (naftifine hydrochloride) is not systemically absorbed to significant levels following topical application. Animal studies have not shown teratogenicity, and no adequate human studies exist. Systemic exposure is minimal, but as a precaution, use during pregnancy only if clearly needed. There is no known first, second, or third trimester risk based on limited data. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to naftifine or any component of the formulation."]
| Precautions | ["For external use only.","Avoid contact with eyes, nose, mouth, or mucous membranes.","Discontinue if irritation or allergic reaction occurs.","Use in pregnancy only if clearly needed (limited data)."] |
Loading safety data…
| Fetal Monitoring |
| No specific maternal or fetal monitoring is required due to negligible systemic absorption. However, monitor for local skin reactions or allergic contact dermatitis at application site. |
| Fertility Effects | No known effects on fertility based on animal studies with topical application. No human data available. |